Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Novel Fluorescent Ductal Needle for Localization and Sampling of High-risk Breast Micro Lesions

NCT: NCT06994416 · RECRUITING

NCT IDNCT06994416
StatusRECRUITING
Start Date2025-06-01
Completion2026-05-31
SponsorThe Fourth Affiliated Hospital of China Medical University (OTHER)
First posted
Last updated

Brief Summary

This retrospective cohort study investigates the differences in the reliability of rapid pathology compared to postoperative pathology when utilizing a novel fluorescent localization needle equipped with a controllable shedding quantum dot chiral nanofluorescent coating, in contrast to traditional localization techniques for breast duct lesions. The primary goal is to evaluate the clinical effectiveness of this innovative fluorescent localization needle in facilitating accurate pathological diagnoses of micro lesions situated within breast ducts.

Frequently Asked Questions

What is A Novel Fluorescent Ductal Needle for Localization and Sampling of High-risk Breast Micro Lesions?

A Novel Fluorescent Ductal Needle for Localization and Sampling of High-risk Breast Micro Lesions is a clinical trial registered under NCT06994416. Current status: RECRUITING.

What is the status of NCT06994416?

The current status of NCT06994416 (A Novel Fluorescent Ductal Needle for Localization and Sampling of High-risk Breast Micro Lesions) is: RECRUITING.

When did A Novel Fluorescent Ductal Needle for Localization and Sampling of High-risk Breast Micro Lesions start?

A Novel Fluorescent Ductal Needle for Localization and Sampling of High-risk Breast Micro Lesions started on 2025-06-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.